Also, high administered peptide amount of [177Lu]Lu-HA-DOTATATE (a somatostatin receptor agonist) leaded to lower uptake in neuroendocrine tumors overexpressing somatostatin receptors33. This evidence concerns the gene SST and neuroendocrine neoplasm.